Compare AngloGold Ashanti Limited (AU) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AngloGold Ashanti Limited vs Heron Therapeutics Inc — how do they compare? AngloGold Ashanti Limited trades at $79.44 (market cap $40.62B), while Heron Therapeutics Inc trades at $0.42 (market cap $82.52M). The key difference: AngloGold Ashanti Limited is far larger — about 492.2× Heron Therapeutics Inc's market cap, and AngloGold Ashanti Limited pays a 5.73% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| AU | HRTX | |
|---|---|---|
Market Cap | $40.62B | $82.52M |
Sector | Basic Materials | Health |
52-Week High | $128.26 | $2.04 |
52-Week Low | $46.25 | $0.39 |
Enterprise Value | $39.75B | $180.42M |
Dividend Yield | 5.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AngloGold Ashanti (AU) trades at $79.76, down 2.85% amid bearish technical signals. The stock shows strong fundamentals with 2025 revenue growth to $9.89B and net income of $2.64B, supported by a 31.11% net margin. Recent Q1 2026 earnings beat expectations at $2.52 EPS versus $2.27 forecast. Analyst consensus remains positive with a $118.60 price target, though technical indicators show selling pressure with support at $77-79 levels.
The outlook remains favorable given robust cash flow growth and geographic diversification, but faces risks from gold price volatility and recent technical weakness. With 64% analyst buy ratings and significant upside to price targets, the stock presents value opportunity for patient investors despite near-term bearish momentum.
HRTX trades at $0.42 with a slight 0.6% daily gain, but technical indicators show a bearish trend with moving averages signaling sell pressure. The company reported Q1 2026 revenue of $151M with a net loss of $31M, continuing negative profitability trends. Recent news highlights patent litigation developments and management reaffirming full-year guidance despite quarterly misses.
While analyst consensus remains overwhelmingly bullish (95% buy ratings), fundamental challenges persist with negative earnings and cash flow. Investment opportunity exists if the company can achieve profitability turnaround, but risks include ongoing operational losses, competitive pressures in biotechnology, and patent litigation uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AngloGold Ashanti Limited
Anglogold Ashanti Ltd is one of the largest gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from Africa which includes Ghana, Guinea, Mali, the Democratic Republic of the Congo, and Tanzania.
Read more on AU →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
